SEARCH

SEARCH BY CITATION

Keywords:

  • Collagen;
  • glycoprotein VI;
  • integrin α2β1;
  • platelet;
  • receptors;
  • signal transduction

Abstract

  1. Top of page
  2. Abstract
  3. Introduction
  4. Collagen receptors on platelets
  5. Signal transduction induced by collagen
  6. Evidence that each collagen type utilyzes a unique set of platelet receptors
  7. Note in proof
  8. Acknowledgements
  9. References

Platelet adhesion to and activation by exposed subendothelial collagen plays a critical role in normal haemostasis and pathological thrombosis. Recent advances in elucidating the mechanisms underlying platelet–collagen interaction support a ‘two-site, two-step’ model. Direct platelet binding to integrin α2β1 mainly sustains adhesion and allows recognition of glycoprotein VI. The latter interaction is responsible for characteristic intracellular signalling events leading to p72Syk and PLCγ2 activation. The present review describes the known collagen receptors on platelets and discusses the current understanding of signal transduction promoted by collagen.


Introduction

  1. Top of page
  2. Abstract
  3. Introduction
  4. Collagen receptors on platelets
  5. Signal transduction induced by collagen
  6. Evidence that each collagen type utilyzes a unique set of platelet receptors
  7. Note in proof
  8. Acknowledgements
  9. References

Platelets play two key roles in haemostasis: upon activation they create a physical barrier that limits blood loss, and they accelerate thrombin generation by providing a surface which catalyzes at least two procoagulant reactions, the conversion of factor X to Xa and of prothrombin to thrombin. These processes are initiated by platelet interactions with the exposed subendothelium at sites of vascular injury [ 1].

At high shear rates the rapid and reversible interaction between glycoprotein (GP) Ib-IX-V and von Willebrand factor (vWF) adherent on collagen types I, III [ 2] and VI [ 3, 4], is crucial for slowing the platelets thereby allowing them to undergo stable binding with other elements of the damaged vessel wall [ 5, 6]. One of the major subendothelial structures that directly reacts with platelets is collagen, which not only offers a substrate for adhesion but also induces platelet activation [ 7, 8]. Indeed, collagen is considered the most thrombogenic matrix component and, together with thrombin, the physiologically strongest platelet agonist [ 9]. Platelet–collagen interactions play therefore a critical role in physiological haemostasis, and understanding this process will help to dissect some events involved in pathological thrombosis. Several reviews have been recently published dealing with different aspects of this interaction [ 7, 10[11][12][13]–14].

An emerging model of the direct platelet–collagen interaction supports the ‘two-site, two-step’ hypothesis originally proposed 10 years ago [ 15, 16], based on evidence that integrin α2β1 mediates firm adhesion to collagen, thereby allowing platelet interaction with a lower affinity receptor, GPVI, mainly responsible for activation ( Figure 1). In the present work we will describe the known collagen receptors on platelets and discuss the current understanding of intracellular signalling promoted by collagen. This review does not cover the important search for platelet-reactive structures of the collagen molecule [ 17, 18].

image

Figure 1. Current model of direct platelet–collagen interactions and signal transduction. Initially integrin α2β1 mediates firm platelet adhesion to exposed subendothelial collagen thereby allowing binding of a second receptor that mainly supports platelet activation. This receptor is composed at least by GPVI noncovalently associated with the homodimer FcRγ-chain [ 105, 106]. Upon GPVI clustering, the two tyrosine residues present in the ITAM of the FcRγ-chain become phosphorylated by a member of the Src family (probably Fyn). This allows association of the tyrosine kinase Syk to the FcRγ-chain, via its tandem SH2 domain (yellow squares) and promotes activation of its catalytic domain (blue rectangle) [ 13]. The activation of Syk by a mechanism that appears to involve the Src tyrosine kinase Lyn regulates through SLP-76 and downstream SLAP-130 the function of PLCγ2 [ 116]. Activated PLCγ2 generates the second messengers DAG and IP3, which promote activation of PKC and increase in cytosolic Ca2+, respectively. A second signalling pathway following GPVI engagement is suggested by the recruitment of PI 3-kinase to the phosphorylated ITAM of the FcRγ-chain, via the tandem SH2 domain of its regulatory subunit (light yellow) [ 90]. The consequent activation of the catalytic subunit (rose) of PI 3-kinase may lead to generation of PIP3, a second messenger that supports membrane binding of proteins with pleckstrin homology domains. LAT has been proposed to sustain at least two roles: it could promote association between Syk and SLP-76 [ 116], and it could mediate recruitment of PI 3-kinase to the GPVI receptor complex [ 90]. Abbreviations in the figure: DAG = 1,2-diacyglycerol; FcR = Fc receptor; GP = glycoprotein; PI 3 = inositol 1,4,5-trisphosphate; ITAM = immunoreceptor tyrosine-based activation motif; LAT = linker for activation of T cells; PI 3-kinase = phosphatidylinositol 3-kinase; PIP3 = phosphatidylinositol 3,4,5-trisphosphate; PLCγ2 = phospholipase Cγ2; PKC = protein kinase C; SH2 = Src homology 2; SLAP-130 = SLP-76-associated phosphoprotein of 130 kDa; SLP-76 = Src homology 2 domain-containing leukocyte protein of 76 kDa.

Download figure to PowerPoint

Collagen receptors on platelets

  1. Top of page
  2. Abstract
  3. Introduction
  4. Collagen receptors on platelets
  5. Signal transduction induced by collagen
  6. Evidence that each collagen type utilyzes a unique set of platelet receptors
  7. Note in proof
  8. Acknowledgements
  9. References

Over the years many studies have identified potential platelet receptors for collagen. This is a difficult interaction to dissect because: of the 18 described collagen types at least 7 are present in the vessel wall [ 19]; collagen is an insoluble macromolecular protein at physiologic pH making analysis of cell–protein interactions difficult [ 20]; and many activation end-points, including membrane GP trafficking, granule secretion and aggregation, progress simultaneously when platelets bind collagen [ 12]. In spite of these obstacles, several proteins on the platelet surface, both integrin and nonintegrin, have been shown to possess characteristics consistent with being specific collagen receptors.

Integrin α2β1 (glycoprotein Ia-IIa)

Integrin α2β1, which is identical with the platelet membrane GP Ia-IIa, the very late activation antigen-2 on activated T cells [ 21] and the class II extracellular matrix receptor on fibroblasts [ 22], has recently been reviewed in depth [ 23]. The α2 (GPIa) and β1 (GPIIa) subunits have apparent molecular weights of 165 kDa (reduced) and 130 kDa, respectively. The aminoacid (aa) sequences were deduced from their corresponding cDNA [ 24, 25]. Both subunits possess a short C-terminal cytoplasmic tail, a single hydrophobic membrane spanning region and a large extracellular domain. The α2 chain, like most other integrin α subunits, does not undergo post-translational cleavage. Its extracellular domain contains a 7-fold repeat segment which includes a EF hand motif with three cation binding sites thought to be involved in ligand binding [ 26]. Just distal to these, there is a segment of 191 aa called the I (inserted)-domain, which is homologous to the collagen-binding A domain of vWF [ 24]. In fact, the α2 I-domain has been shown to bind collagen [ 27, 28], and a recombinant α2 I-domain fusion protein inhibits collagen-induced platelet adhesion [ 29]. While the α2 I-domain is sufficient and essential for platelet-collagen binding, other structures, such as the adjacent EF hand motif can optimize it [ 26]. In addition, the extracellular domain of the β1 subunit, which is composed of a proximal portion of four internally folded cysteine-rich repeat units and a distal portion of highly conserved sequence shared with other β integrins, is thought to regulate the binding affinity of the α2 I-domain [ 30, 31].

The first indication that integrin α2β1 might be a physiologically relevant collagen receptor came from the observation of a female patient with excessive post-traumatic bleeding and menorrhagia [ 32]. This patient's platelets, which selectively failed to aggregate or undergo shape change in response to collagen, were found to contain only 15–20% of the normal amount of GPIa [ 32]. Furthermore, under flow conditions these platelets exhibited a markedly decreased adhesion to and failure to spread on a subendothelial surface [ 33]. A second patient with GPIa deficiency has been reported, whose haemorrhagic symptoms and biochemical defect surprisingly disappeared when she entered menopause [ 34]. In addition, a patient with an acquired bleeding disorder associated with an autoantibody against GPIa [ 35] and another with a complete deficiency of GPIa in the context of a myeloproliferative disorder [ 36] have been described.

The interaction of integrin α2β1 with collagen requires Mg2+ (which can be substituted by Mn2+, Co2+, Cu2+, Fe2+ and Zn2+) and is inhibited by Ca2+ [ 37, 38], thus explaining the observation that platelet adhesion to collagen is markedly increased in the presence of Mg2+ [ 39]. Saelman et al. demonstrated that collagens I through VIII are variously able to support platelet adhesion and that this can be completely inhibited, under conditions of both stasis and flow, by a monoclonal antibody directed against GPIa [ 40]. Noteworthy, collagen type V does not support adhesion under flow, and at shear rates of 1600/s adhesion to collagen type III is only inhibited by 85% [ 40]. Interestingly, at high shear rates inhibition of platelet adhesion to the most reactive collagens, types I through IV, requires three times more antibody than needed at low shear [ 40], suggesting that the role of integrin α2β1 is more critical at high shear. Consistent with this are studies showing that the binding avidity of integrin α2β1 can be modulated with antibodies against the β1 subunit [ 30, 31], and enhanced following activation of protein kinase C [ 41]. Studies with soluble collagen indicate that integrin α2β1 becomes activated following platelet interaction with thrombin, ADP and a GPVI specific agonist [ 42]. Finally, CD47/IAP (integrin-associated protein), a receptor for the cell binding domain of thrombospondin-1, has recently been shown to coimmunoprecipitate with integrin α2β1 and to augment its function [ 43]. These data suggest the interesting hypothesis that variations in integrin α2β1 binding avidity may have physiological significance.

The number of integrin α2β1 molecules on the platelet surface significantly varies between normal individuals [ 44], ranging between 800 and 1800 [ 21, 44, 45]. While platelet activation does not increase the number of surface molecules by more than 5% [ 44], the interindividual variation of integrin α2β1 surface levels by itself correlates with platelets' ability to adhere to collagen types I and III under static conditions [ 44] and to collagen type I under flow [ 46]. This heterogeneity is associated with three α2 gene alleles, defined by eight nucleotide polymorphisms [ 46, 47]. Initially two silent, linked polymorphisms located at nucleotides 807 (TTT/TTC at codon Phe224) and 873 (ACA/ACG at codon Thr246) were described [ 47]. Although the aa sequence of the α2 subunit is not affected by the polymorphisms, the 807T/873A pair is associated with higher surface levels of integrin α2β1 than the 807C/873G pair [ 47]. Subsequently, a similarly silent but much rarer polymorphism located at nucleotide 837 (C or T) and linked to the Br polymorphism [ 48] was also identified [ 46]. Allele 1 (807T/837T/873A/Brb) has a frequency of ≈ 39% and is associated with increased levels of integrin α2β1, while allele 2 (807C/837T/873G/Brb) with a frequency of ≈ 53% and allele 3 (807C/837C/873G/Bra) with a frequency of ≈ 8% are both associated with lower levels of integrin α2β1 [ 46]. In a case control study, a significantly higher prevalence of individuals homozygous for 807T/873A were found among patients with myocardial infarction [ 49], and multivariate analysis confirmed this genotype as an independent risk factor for myocardial infarction [ 49]. Recently, the 807T allele was found to strongly correlate with the development of nonfatal myocardial infarction [ 50] and stroke [ 51] in younger patients. These three studies indicate that the inherited variation of platelet surface integrin α2β1 is a significant risk factor for acute thrombotic events. Interestingly, the frequency of the 807C allele, which is associated with a lower integrin α2β1 density and a decreased haemostatic function, has been shown to be significantly higher among type 1 von Willebrand disease patients than among normal individuals [ 52]. This observation confirms that integrin α2β1 is a significant contributor to the haemostatic process, and suggests that its surface variability among patients with similar vWF levels may account for the very different bleeding phenotypes.

In summary, integrin α2β1 is considered to be the major receptor mediating direct and permanent platelet adhesion to collagen [ 11], thus perfecting the initial vWF-dependent tethering at high shear rates [ 6] and facilitating engagement of lower affinity receptors, such as GPVI. The extent of integrin α2β1 contribution to subsequent platelet activation is less clear (see below). The clinical relevance of integrin α2β1 polymorphisms with its variable expression on the platelet surface has been addressed in a recent review [ 53].

Glycoprotein VI (p62)

GPVI, a not yet cloned 62 kDa (reduced) platelet membrane protein, was first described 20 years ago [ 54], and its involvement in platelet–collagen interactions was postulated one decade later based on the following observations. An antibody that recognized a 62/57 kDa platelet membrane protein was identified in the serum of a patient with autoimmune thrombocytopenia whose platelets were selectively defective in collagen-induced aggregation [ 55]. This antibody could recognize a 62 kDa protein and induce aggregation of normal platelets [ 55], but did not react with platelets from a GPVI-deficient patient [ 56], thus identifying the 62 kDa protein as GPVI and demonstrating its involvement in collagen-induced platelet activation. To date, 3 GPVI-deficient patients [ 56[57]–58], and two patients with an autoantibody against GPVI [ 55, 59], have been described. All patients exhibit a mild bleeding tendency and slightly prolonged bleeding times. While their platelets have an essentially normal response to other physiologic agonists, they show a defective aggregation in response to collagen despite normal expression of integrin α2β1. Although GPVI has been implicated in platelet adhesion to collagen under static conditions [ 58, 60, 61], this is probably a consequence of its ability to induce platelet activation. Under flow conditions GPVI involvement relates to second phase adhesion, a process which is secondary to integrin αIIbβ3 activation [ 62]. GPVI has been demonstrated to recognize both the tertiary (triple-helical) and quaternary (polymeric) structure of collagen and is considered to be the crucial receptor mediating platelet activation [ 63]. The intracellular signalling events induced by GPVI engagement will be discussed below.

CD36 (GPIV)

CD 36 [ 64], an 88 kDa GP functioning as a scavenger receptor and cell-adhesion molecule [ 65], is expressed on several cell types, including platelets, monocytes/macrophages, reticulocytes/erythrocytes, microvascular endothelial cells and melanoma cells, and has been implicated in a variety of pathophysiological situations ranging from haemostasis and thrombosis to malaria, inflammation, lipid metabolism and atherogenesis [ 65].

It has been estimated that there are about 20 000 CD36 molecules on the platelet surface [ 66]. This GP has been proposed as a collagen receptor based on the observation that antibodies against it could inhibit collagen induced platelet activation and aggregation [ 67, 68]. In addition, incubation of normal platelets with Fab fragments of a monospecific polyclonal anti-CD36 antibody inhibited the early stages of adhesion to collagen type I under static [ 67] and under flow conditions [ 69]. Diaz-Ricart et al. [ 69] using citrated reconstituted whole blood also showed that platelets from CD36-deficient individuals have a decreased early adhesion. However, 3% to 11% of healthy Japanese blood donors lack CD36 without any apparent bleeding disorder [ 70]. Moreover, collagen induced aggregation [ 71] and metabolic responses [ 72] in CD36-deficient platelets have been shown to be normal. The discrepancies between these observations and the previous studies might reside in the divalent cation conditions employed. Utilyzing heparinized blood, Saelman et al. demonstrated that CD36-deficient platelets adhere normally to collagen type I, III, and IV under both static and flow conditions [ 73]. Remarkably, while collagen type V is not adhesive during flow [ 40], under static conditions adhesion of both homozygous and heterozygous CD36 deficient platelets to this collagen type was strongly reduced [ 73]. The peculiar behaviour of collagen type V was confirmed by Kehrel et al. who showed that CD36-deficient platelets aggregate normally with collagen types I and III but not in response to collagen type V [ 74]. Indeed, CD36-deficient platelets appeared even more sensitive to types I and III collagens than normal platelets [ 74], suggesting an inhibitory co-operation between CD36 and other collagen receptor(s). Taken together these observations seem compatible with the hypothesis that CD36 might be involved in the very first adhesion of platelets to collagen, but it is essential only for interaction with collagen type V. This may be relevant to the development of thrombotic events because collagen type V is increased in atherosclerotic plaques [ 75].

P65 protein

Chiang and Kang have isolated and purified from human platelets a 65 kDa protein which behaves as a receptor for collagen type I [ 76]. They subsequently demonstrated that platelet aggregation induced by collagen type I can be inhibited with poly- and monoclonal antibodies against the 65 kDa protein [ 77, 78]. Finally, they succeeded in cloning a cDNA strand that encodes the 65 kDa receptor, showing that the recombinant protein binds to and inhibits platelet aggregation and ATP release in response to collagen type I [ 79]. They also have identified a portion of the receptor molecule likely to represent the collagen binding site [ 80]. Interestingly enough, this body of work demonstrates that the 65 kDa protein is not involved in the platelet interaction with collagen type III.

P85/90 protein

Deckmyn et al. described a patient with an antibody directed against a 85/90 kDa platelet membrane GP which interfered with collagen-induced platelet aggregation [ 81]. Despite similar electrophoretic behaviour, purified CD36 was not recognized by the patient's antibody indicating that the 85/90 kDa GP is a distinct structure [ 81]. Little else is known about this putative collagen receptor.

Signal transduction induced by collagen

  1. Top of page
  2. Abstract
  3. Introduction
  4. Collagen receptors on platelets
  5. Signal transduction induced by collagen
  6. Evidence that each collagen type utilyzes a unique set of platelet receptors
  7. Note in proof
  8. Acknowledgements
  9. References

One set of early events in platelet activation induced by most agonists involves the hydrolysis of inositol phospholipids [ 82]. Following receptor engagement, activated phospholipase C (PLC) cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) to the second messengers inositol 1,4,5-trisphosphate (IP3) and 1,2-diacyglycerol (DAG). IP3 increases the cytosolic Ca2+ concentration by releasing stored Ca2+ from the dense tubular system and DAG activates protein kinase C. These events promote thromboxane A2 (TxA2) generation, shape change, granule secretion, activation of the fibrinogen receptor integrin αIIbβ3 (glycoprotein IIb-IIIa) and ultimately platelet aggregation [ 82].

Platelets contain at least two forms of PLC, β and γ, which are regulated through different mechanisms involving heterotrimeric G-proteins and protein tyrosine kinases (PTK), respectively [ 83]. Accordingly, thrombin and TxA2, whose platelet receptors are known to signal by means of G proteins, have been shown to activate PLCβ. As for collagen, it induces a PTK-dependent mechanism for phosphorylation of PLCγ2, the predominant isoform of PLCγ in platelets, which is not activated following stimulation with thrombin or the stable TxA2 analogue U46619 [ 84, 85]. These observations confirm that the two strongest physiological platelet agonists, thrombin and collagen, operate through different signalling pathways [ 86].

Collagen promotes tyrosine phosphorylation of numerous proteins in platelets [ 87]. While the phosphorylation of several of them depends on integrin αIIbβ3 engagement and platelet aggregation, at least two proteins of 38 and 72 kDa, respectively, are rapidly and markedly phosphorylated even when events downstream of PLC are selectively inhibited [ 88], suggesting their involvement in early signalling between collagen receptor engagement and PLCγ2 activation. The 72 kDa protein has been identified as Syk [ 89] and the 38 kDa protein is likely to be the human equivalent [ 90] of LAT (linker for activation of T cells), a recently cloned adapter protein implicated in T-cell receptor signalling [ 91]. Furthermore, the 38 kDa protein, Syk and PLCγ2 also become phosphorylated following cross-linking of the low affinity receptor for IgG complexes present on platelets, FcγRIIA (CD 32), suggesting that collagen-induced platelet activation might be mediated through the same pathway as that used by immune-receptors [ 88].

Collagen signals by a similar pathway as immune receptors

Immune receptors operate through sequential activation of members of the Src and Syk kinase families with a pivotal role played by a tyrosine-based motif located in the cytoplasmic tail of the receptor itself or its associated chain [ 92]. This motif, identified in 1989 and now known as the immunoreceptor tyrosine-based activation motif (ITAM), is defined by the sequence YXXL/IX(6–8)YXXL/I, where X represents any amino acid [ 92]. Upon receptor activation, the ITAM becomes phosphorylated on both conserved tyrosine residues by a member of the Src family. This allows association with the tandem Src homology 2 (SH2) domains of Syk, leading to its activation and downstream signalling, including PLCγ2 phosphorylation.

In order to identify ITAM-containing proteins that undergo phosphorylation following collagen stimulation, Gibbins et al. have incubated platelet lysates with the tandem SH2 domains of Syk expressed as a glutathione-S-transferase fusion protein [ 93]. They found that the Syk tandem SH2 domains precipitated a tyrosine phosphorylated protein with a molecular weight of 12/25 kDa (reduced/nonreduced), which was identified as the Fc receptor (FcR) γ-chain [ 93]. The FcR γ-chain is expressed in cells as a homodimer linked by a disulfide bridge. It plays a role in surface expression and function of the receptor for IgA (FcαR), the high affinity receptors for IgE (FcεRI) and IgG (FcγRI), and the low affinity IgG receptor (FcγRIII) [ 94[95][96]–97]. It should be noted that FcγRIIA, the low affinity receptor for immune complexes expressed on platelets, does not associate with the FcR γ-chain but contains an ITAM sequence on its own cytoplasmic tail. This immune receptor is not directly involved in collagen signalling because activation of the ITAM sequence by receptor clustering does not induce phosphorylation of the FcR γ-chain. The concept that collagen activates platelets through a pathway involving tyrosine phosphorylation of FcR γ-chain, Syk and PLCγ2, a signalling sequence characteristic of immune receptors, was confirmed in knock-out mice lacking either the FcR γ-chain or Syk [ 98].

GPVI and FcR γ-chain constitute a collagen receptor complex

Studies performed with collagen-like, triple helix peptides based on a glycine-proline-hydroxyproline repeat sequence, which cannot bind to integrin α2β1, indicated that platelet activation and aggregation [ 99], and tyrosine phosphorylation and activation of Syk and PLCγ2 [ 100], can be achieved through a different collagen receptor. This was supported by Ichinohe et al. [ 101], who observed that GPVI cross-linking induced platelet activation in a manner similar to collagen: it is not inhibited by elevation of intracellular c-AMP [ 86], and promotes a PTK-dependent activation of c-Src, Syk, and PLCγ2 [ 102, 103]. Furthermore, the same group reported that GPVI-deficient platelets expressing normal amounts of α2β1 exhibited a defect in tyrosine phosphorylation of Syk, Fak, PLCγ2 and Vav [ 104], while activation of c-Src did occur and could be abolished by a mAb against α2β1 [ 104]. The final link between GPVI and the collagen signalling pathway previously described was established by demonstrating that GPVI and the FcR γ-chain are both expressed as a functional unit on the surface of normal platelets and proportionally decreased in GPVI-deficient platelets [ 105, 106]. This concept was independently confirmed by Polgár et al. who demonstrated that convulxin, a powerful platelet activator isolated from the venom of Crotalus durissus terrificus, selectively binds to GPVI inducing a signal transduction like collagen, and that convulxin subunits are able to inhibit both platelet aggregation and tyrosine phosphorylation in response to collagen [ 107].

Recent reports are further clarifying the early signalling events initiated by GPVI cross-linking. First, Ezumi et al. employing Sepharose 4B beads coupled with the specific GPVI agonist convulxin [ 107] for affinity precipitation of the collagen receptor, showed that the Src family PTKs Fyn and Lyn are constitutively associated with the GPVI/FcR γ-chain complex [ 108]. Fyn becomes rapidly phosphorylated upon collagen stimulation and the selective Src family inhibitor PP1 (4-amino-5-[4-methy1pheny1]-7-[t-buty1]pyrazo1 o[3,4-d]pyrimidine [ 109]) inhibits in a concentration-dependent manner tyrosine phosphorylation of FcR γ-chain, Syk, and PLCγ2, granule release reaction, and aggregation [ 108, 110]. This finding demonstrated that Fyn and Lyn are functionally relevant for collagen induced platelet activation. Moreover, the inhibition of FcR γ-chain and Syk phosphorylation by PP1 suggest that either Fyn, Lyn, or both, play a major role in early signalling. Briddon and Watson have suggested that Fyn is constitutively associated either directly with the FcR γ-chain or with another component of the collagen receptor, and that Lyn is involved downstream of the FcR γ-chain because, contrary to Fyn, it associates with several other tyrosine-phosphorylated proteins, including PLCγ2, in a much larger signalling complex [ 110]. Second, Clements et al. have demonstrated that aggregation and tyrosine phosphorylation of PLCγ2 is absent in SLP-76 deficient platelets [ 111]. SLP-76 (Src homology 2 domain-containing leukocyte protein of 76 kDa) is believed to be an essential adapter protein in T cells: it becomes tyrosine-phosphorylated upon T-cell receptor stimulation [ 112], is necessary for tyrosine phosphorylation of PLCγ1 and activation of the Ras pathway in Jurkat cells [ 113], and is required for normal thymocyte development in mice [ 114, 115]. As collagen signals by a pathway similar to immune receptors, it is no surprise that SLP-76 appears to be a crucial adapter protein in collagen-stimulated platelets as well [ 111]. Here it provides, together with downstream SLAP-130 (SLP-76-associated phosphoprotein of 130 kDa), an important link between Syk activation and PLCγ2 regulation [ 116].

In summary, although the signalling pathway downstream of GPVI engagement is not yet completely elucidated, some of its components have been accurately described ( Fig. 1). According to the current model, GPVI is noncovalently associated with FcR γ-chain and with at least one member of the Src family of tyrosine kinases, Fyn. Upon GPVI clustering, the conserved tyrosine residues on the FcR γ-chain ITAM become phosphorylated, presumably by Fyn. This promotes recruitment to the receptor complex of tyrosine kinase Syk, mediated by the association of its tandem SH2 domain with the phosphorylated FcR γ-chain. The activation of Syk, by a mechanism that appears to involve Lyn, leads by means of SLP-76 to tyrosine phosphorylation and activation of PLCγ2 and to the subsequent formation of the two important second messengers, IP3 and DAG.

The interesting hypothesis that signalling generated by the GPVI/FcR γ-chain complex might diverge into a second pathway involving phosphatidylinositol (PI) 3-kinase has been recently proposed by Gibbins et al. [ 90]. PI 3-kinase mediates inositol phospholipid metabolism by converting phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3), a second messenger involved in membrane binding of proteins with pleckstrin homology domains and in the regulation of some protein kinase C isoforms [ 117]. Platelets contain at least one isoform of PI 3-kinase, consisting of a p110 subunit whose subcellular localisation and catalytic activity are regulated by a p85 subunit [ 117]. Gibbins et al. have demonstrated that the p85 regulatory subunit is able to bind both to the tyrosine phosphorylated ITAM sequence of the FcR γ-chain and LAT, the above mentioned 38 kDa protein which becomes phosphorylated in collagen and convulxin stimulated platelets [ 90], thereby providing the potential for a second signalling pathway initiated by GPVI engagement.

The role of other collagen receptors

While the described body of work represents strong evidence for a primary role played by GPVI in collagen induced signalling, relatively little is known about the contribution of other collagen receptors. GPVI-deficient platelets still manifest activation of Src and tyrosine phosphorylation of cortactin in response to collagen, which can be eliminated with an inhibitory mAb against α2β1 [ 104], suggesting that engagement of this integrin promotes intracellular signalling. Consistent with this proposal, collagen induced tyrosine phosphorylation of Syk and PLCγ2 in normal platelets is compromised by blocking integrin α2β1 [ 118] or by proteolytic cleavage of the β1 subunit [ 119]. Taken together, these results indicate that integrin α2β1 may sustain a co-operative role in collagen induced activation of PTKs. However, direct crosslinking of α2β1 with mAbs induces an increase in tyrosine phosphorylation of Syk and PLCγ2 which is dependent on costimulation of FcγRIIA, because specific F(ab′)2 fragments are ineffective [ 118]. The role of FcγRIIA is not yet clarified and this receptor is not specific to collagen signalling. In fact, antibodies directed against other antigens on the platelet surface, such as CD 36 (see below), heparin complexed to PF4 [ 120] or vWF bound to GPIb [ 121] lead to platelet activation through the FcγRIIA receptor.

CD36 is physically associated with the Src family PTKs Fyn, Yes and Lyn in human platelets [ 122], and, similarly to integrin α2β1, mAbs against CD36 can induce platelet secretion and aggregation in a FcγRIIA-dependent manner [ 123], implying its involvement in intracellular signalling as well. However, CD36 appears to be essential only for platelet interaction with collagen type V [ 74]. Finally, a role for the collagen type I specific receptor p65 is suggested by the fact that an anti-p65 mAb inhibits collagen-induced platelet aggregation [ 78]. In summary, besides GPVI other collagen receptors also appear to mediate intracellular signalling; however, their relative contributions and relevance with respect to different collagen types is unclear.

Evidence that each collagen type utilyzes a unique set of platelet receptors

  1. Top of page
  2. Abstract
  3. Introduction
  4. Collagen receptors on platelets
  5. Signal transduction induced by collagen
  6. Evidence that each collagen type utilyzes a unique set of platelet receptors
  7. Note in proof
  8. Acknowledgements
  9. References

Several observations indicate that each collagen type might interact with platelets through a specific set of receptors. For example, platelet adhesion to collagen type III cannot be completely inhibited by monoclonal antibodies against integrin α2β1 [ 40], and surface level of integrin α2β1 correlates with the lag time before onset of aggregation induced by collagen type I but not by type III [ 44]. Collagen type IV is among the strongest inducers of platelet adhesion [ 40] but does not promote platelet aggregation [ 124] nor activation [ 8]. As already discussed, the 65 kDa receptor studied by Chiang and Kang is specific for collagen type I [ 125] and CD36 is critical only for collagen type V [ 79]. Moreover, most of the studies delineating collagen induced intracellular signalling have been performed with specific agonists for GPVI or collagen type I, so that presently it is not known whether other collagen types might activate different pathways. The existence of diverse, possibly collagen-type specific, mechanisms of collagen–platelet interactions and the relative contributions of the several identified receptors needs further study.

The use of receptor specific agonists, such as aggretin for integrin α2β1 [ 126], convulxin for GPVI [ 107] and collagen-like peptides, which have recently been shown to be specific for GPVI [ 127, 128], together with studies employing receptor specific inhibitory antibodies in platelets simulated with different collagen types should provide some insight into this complex and important area of research.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Introduction
  4. Collagen receptors on platelets
  5. Signal transduction induced by collagen
  6. Evidence that each collagen type utilyzes a unique set of platelet receptors
  7. Note in proof
  8. Acknowledgements
  9. References

We are indebted to Kenneth J. Clemetson, PhD, for his careful review of the manuscript and helpful suggestions. L. Alberio was supported by a grant from the Swiss National Science Foundation. Additional support was provided by the W. K. Warren Medical Research Institute, and grant HL53585 from the National Institute of Health.

References

  1. Top of page
  2. Abstract
  3. Introduction
  4. Collagen receptors on platelets
  5. Signal transduction induced by collagen
  6. Evidence that each collagen type utilyzes a unique set of platelet receptors
  7. Note in proof
  8. Acknowledgements
  9. References
  • 1
    Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemost, 1997;78:611 6.
  • 2
    Pareti FI, Niiya K, McPherson JM, Ruggeri ZM. Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. J Biol Chem, 1987;262:13835 41.
  • 3
    Rand JH, Patel ND, Schwartz E, Zhou SL, Potter BJ. 150-kD von Willebrand factor binding protein extracted from human vascular subendothelium is type VI collagen. J Clin Invest, 1991;88:253 9.
  • 4
    Rand JH, Glanville RW, Wu XXet al. The significance of subendothelial von Willebrand factor. Thromb Haemost, 1997;78:445 50.
  • 5
    Moroi M, Jung SM, Nomura S, Sekiguchi S, Ordinas A, Diaz-Ricart M. Analysis of the involvement of the von Willebrand factor–glycoprotein Ib interaction in platelet adhesion to a collagen-coated surface under flow conditions. Blood, 1997;90:4413 24.
  • 6
    Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate–receptor interactions in platelet thrombus formation under flow. Cell, 1998;94:657 66.
  • 7
    Kehrel B. Platelet receptors for collagen. Platelets, 1995;6:11 6.
  • 8
    Alberio L & Dale GL. Flow cytometric analysis of platelet activation by different collagen types present in the vessel wall. Br J Haematol, 1998;102:1212 8.
  • 9
    Brass LF. The biochemistry of platelet activation. In: Hoffman R, Benz EJ, Shattil SJ, Furie B & Cohen HJ, editors. Hematology Basic Principles and Practice. New York: Churchill Livingstone; 1991. p.1176 97.
  • 10
    Kehrel B. Platelet–collagen interactions. Sem Thromb Hemost, 1995;21:123 9.
  • 11
    Sixma JJ, Van Zanten H, Huizinga EGet al. Platelet adhesion to collagen: an update. Thromb Haemost, 1997;78:434 8.
  • 12
    Moroi M & Jung SM. Platelet receptors for collagen. Thromb Haemost, 1997;78:439 44.
  • 13
    Watson SP & Gibbins JM. Collagen receptor signalling in platelets: extending the role of the ITAM. Immunol Today, 1998;19:260 4.
  • 14
    Barnes MJ, Knight CG, Farndale RW. The collagen–platelet interaction. Curr Opin Hematol, 1998;5:314 20.
  • 15
    Morton LF, Peachey AR, Barnes MJ. Platelet-reactive sites in collagens type I and type III. Evidence for separate adhesion and aggregatory sites. Biochem J, 1989;258:157 63.
  • 16
    Santoro SA, Walsh JJ, Staatz WD, Baranski KJ. Distinct determinants on collagen support α2β1 integrin-mediated platelet adhesion and activation. Cell Regul, 1991;2:905 13.
  • 17
    Barnes MJ, Knight CG, Farndale RW. The use of collagen-based model peptides to investigate platelet-reactive sequences in collagen. Biopolymers, 1996;40:383 97.
  • 18
    Knight CG, Morton LF, Onley DJet al. Identification in collagen type I of an integrin alpha2 beta1-binding site containing an essential GER sequence. J Biol Chem, 1998;273:33287 94.
  • 19
    Van Der Rest M & Garrone R. Collagen family of proteins. FASEB J, 1991;5:2814 23.
  • 20
    Williams BR, Gelman RA, Poppke DC, Piez KA. Collagen fibril formation: optimal in vitro conditions and preliminary kinetic results. J Biol Chem, 1978;253:6578 85.
  • 21
    Pischel KD, Bluestein HG, Woods VL. Platelet glycoproteins Ia, Ic, and IIa are physicochemically indistinguishable from the very late activation antigens adhesion-related proteins of lymphocytes and other cell types. J Clin Invest, 1988;81:505 13.
  • 22
    Kunicki TJ, Nugent DJ, Staats SJ, Orchekowski RP, Wayner EA, Carter WG. The human fibroblast class II extracellular matrix receptor mediates platelet adhesion to collagen and is identical to the platelet glycoprotein Ia-IIa complex. J Biol Chem, 1988;263:4516 9.
  • 23
    Santoro SA & Zutter MM. The α2β1 integrin: a collagen receptor on platelets and other cells. Thromb Haemost, 1995;74:813 21.
  • 24
    Takada Y & Hemler ME. The primary structure of the VLA-2/collagen receptor alpha 2 subunit (platelet GPIa): homology to other integrins and the presence of a possible collagen-binding domain. J Cell Biol, 1989;109:397 407.
  • 25
    Argraves WS, Suzuki S, Arai H, Thompson K, Pierschbacher MD, Ruoslathi E. Amino acid sequence of the human fibronectin receptor. J Cell Biol, 1987;105:1183 90.
  • 26
    Dickeson SK, Walsh JJ, Santoro SA. Contributions of the I and EF hand domains to the divalent cation-dependent collagen binding activity of the alpha2beta1 integrin. J Biol Chem, 1997;272:7661 8.
  • 27
    Kamata T, Puzon W, Takada Y. Identification of putative ligand binding sites within I domain of integrin alpha 2 beta 1 (VLA-2, CD49b/CD29). J Biol Chem, 1994;271:9659 63 [erratum: J Biol Chem, 1996;271:19008].
  • 28
    Tuckwell DS, Reid KB, Barnes MJ, Humphries MJ. The A-domain of integrin alpha 2 binds specifically to a range of collagens but is not a general receptor for the collagenous motif. Eur J Biochem, 1996;241:732 9.
  • 29
    Depraetere H, Wille C, Gansemans Yet al. The integrin alpha 2 beta 1 (GPIa/IIa) -I-domain inhibits platelet– collagen interaction. Thromb Haemost, 1997;77:981 5.
  • 30
    Chan BM & Hemler ME. Multiple functional forms of the integrin VLA-2 can be derived from a single alpha 2 cDNA clone: interconversion of forms induced by an anti-beta 1 antibody. J Cell Biol, 1993;120:537 43.
  • 31
    Takada Y & Puzon W. Identification of a regulatory region of integrin beta 1 subunit using activating and inhibiting antibodies. J Biol Chem, 1993;268:17597 601.
  • 32
    Nieuwenhuis HK, Akkerman JW, Houdijk WPW, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature, 1985;318:470 2.
  • 33
    Nieuwenhuis HK, Sakariassen KS, Houdijk WPW, Nievelstein PF, Sixma JJ. Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood, 1986;68:692 5.
  • 34
    Kehrel B, Balleisen L, Kokott R, Mesters R, Stenzinger W, Clemetson KJ. Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen induced aggregation and spontaneous loss of the disorder. Blood, 1988;71:1074 8.
  • 35
    Deckmyn H, Chew SL, Vermylen J. Lack of platelet response to collagen associated with an autoantibody against glycoprotein Ia: a novel cause of acquired qualitative platelet dysfunction. Thromb Haemost, 1990;64:74 9.
  • 36
    Handa M, Watanabe K, Kawai Yet al. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Haemost, 1995;73:521 8.
  • 37
    Santoro SA. Identification of a 160′000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. Cell, 1986;46:913 20.
  • 38
    Staatz WD, Rajpara SM, Wayner EA, Carter WG, Santoro SA. The membrane glycoprotein Ia-IIa (VLA-2) complex mediates the Mg2+-dependent adhesion of platelet to collagen . J Biol Chem, 1989;108:1917 24.
  • 39
    Shadle PJ & Barondes SH. Adhesion of human platelets to immobilized trimeric collagen. J Cell Biol, 1982;95:361 5.
  • 40
    Saelman EUM, Nieuwenhuis HK, Hese KMet al. Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (α2β1-integrin) . Blood, 1994;83:1244 50.
  • 41
    Rosfjord EC, Maemura M, Johnson MDet al. Activation of protein kinase C by phorbol esters modulates alpha2beta1 integrin on MCF-7 breast cancer cells. Exp Cell Res, 1999;248:260 71.
  • 42
    Jung SM & Moroi M. Platelets interact with soluble and insoluble collagens through characteristically different reactions. J Biol Chem, 1998;273:14827 37.
  • 43
    Chung J, Wang XQ, Lindberg FP, Frazier WA. Thrombospondin-1 acts via IAP/CD47 to synergize with collagen in alpha2beta1-mediated platelet activation. Blood, 1999;94:642 8.
  • 44
    Kunicki TJ, Orchekowski R, Annis D, Honda Y. Variability of integrin α2β1 activity on human platelets. Blood, 1993;82:2693 703.
  • 45
    Coller BS, Beer JH, Scudder LE, Steinberg MH. Collagen–platelet interactions: evidence for a direct interaction of collagen with platelet GP Ia/IIa and an indirect interaction with platelet GP IIb/IIIa mediated by adhesive proteins. Blood, 1989;74:182 92.
  • 46
    Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the α2 gene define multiple alleles that are associated with differences in platelet α2β1 density. Blood, 1998;92:2382 8.
  • 47
    Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood, 1997;89:1939 43.
  • 48
    Kiefel V, Santoso S, Katzmann B, Mueller-Eckhardt C. The Bra/Brb alloantigen system on human platelets. Blood, 1989;73:2219 23.
  • 49
    Moshfegh K, Wuillemin WA, Redondo Met al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet, 1999;353:351 4.
  • 50
    Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood, 1999;93:2449 53.
  • 51
    Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood, 1999;93:3583 6.
  • 52
    Di Paola J, Federici AB, Mannucci PMet al. Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood, 1999;93:3578 82.
  • 53
    Santoro SA. Platelet surface collagen receptor polymorphisms: variable receptor expression and thrombotic/ hemorrhagic risk. Blood, 1999;93:3575 7.
  • 54
    Clemetson KJ, McGregor JL, James E, Dechevanne M, Luscher EF. Characterization of the platelet membrane glycoprotein abnormalities in Bernard–Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. J Clin Invest, 1982;70:304 11.
  • 55
    Sugiyama T, Okuma M, Ushikubi F, Sensaki S, Kanaji K, Uchino H. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood, 1989;69:1712 20.
  • 56
    Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelet deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest, 1989;84:1440 5.
  • 57
    Ryo R, Yoshida A, Sugano Wet al. Deficiency of P62, a putative collagen receptor, in platelets from a patient with defective collagen-induced platelet aggregation. Am J Hematol, 1992;39:25 31.
  • 58
    Arai M, Yamamoto N, Moroi M, Akamatsu N, Fukutane K, Tanoue K. Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency. Br J Haematol, 1995;89:124 30.
  • 59
    Takahashi H, Hanano M, Moroi M, Shibata A. Platelet membrane glycoprotein VI (GPVI) is necessary for collagen-induced aggregation and adhesion and anti-GPVI antibody induces platelet aggregation: an evidence from a patient with systemic lupus erythematosus. Thromb Haemost, 1995;73:1197 (Abstract).
  • 60
    Moroi M, Okuma M, Jung SM. Platelet adhesion to collagen-coated wells: analysis of this complex process and a comparison with the adhesion to matrigel-coated wells. Biochim Biophys Acta, 1992;1137:1 9.
  • 61
    Nakamura T, Kambayashi J, Okuma M, Tandon NN. Activation of the GP IIb-IIIa complex induced by platelet adhesion to collagen is mediated by both alpha2beta1 integrin and GP VI. J Biol Chem, 1999;274:11897 903.
  • 62
    Moroi M, Jung SM, Shinmyozu K, Tomiyama Y, Ordinas A, Diaz-Ricart M. Analysis of platelet adhesion to a collagen-coated surface under flow conditions: the involvement of glycoprotein VI in the platelet adhesion. Blood, 1996;88:2081 92.
  • 63
    Kehrel B, Vierwille S, Clemetson KJet al. Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa and von Willebrand factor do not. Blood, 1998;91:491 9.
  • 64
    Talle MA, Rao PE, Westberg Eet al. Patterns of antigenic expression on human monocytes as defined by monoclonal antibodies. Cell Immunol, 1983;78:83 99.
  • 65
    Daviet L & McGregor JL. Vascular biology of CD36: roles of this new adhesion molecule family in different disease states. Thromb Haemost, 1997;78:65 9.
  • 66
    Ware JA & Coller BS. Platelet morphology, biochemistry, and function. In: Beutler E, Lichtmann MA, Coller BS & Kipps TJ, editors. Williams Hematology. 5th ed. New York: McGraw-Hill; 1995. p.1161 201.
  • 67
    Tandon NN, Kralisz U, Jamison GA. Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem, 1989;264:7576 83.
  • 68
    McGregor GL, Catimel B, Parmentier S, Clezardin P, Dechevanne M, Leung LL. Rapid purification and partial characterisation of human glycoprotein IIIb. Interaction with thrombospondin and its role in platelet aggregation. J Biol Chem, 1989;264:501 6.
  • 69
    Diaz-Ricart M, Tandon NN, Carretero M, Ordinas A, Bastida E, Jamieson G. Platelets lacking functional CD36 (glycoprotein IV) show reduced adhesion to collagen in flowing whole blood. Blood, 1993;82:491 6.
  • 70
    Yamamoto N, Ikeda H, Tandon NNet al. A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka- platelets lack detectable GPIV (CD36). Blood, 1990;76:1698 703.
  • 71
    Yamamoto N, Akamatsu N, Yamazaki H, Tanoue K. Normal aggregations of glycoprotein IV (CD36) -deficient platelets from seven healthy Japanese donors. Br J Haematol, 1992;81:86 92.
  • 72
    Daniel JL, Dangelmaier C, Strouse R, Smith JB. Collagen induces normal signal transduction in platelets deficient in CD36 (platelet glycoprotein IV). Thromb Haemost, 1994;71:353 6.
  • 73
    Saelman EU, Kehrel B, Hese KM, DeGroot PG, Sixma JJ, Nieuwenhuis HK. Platelet adhesion to collagen and endothelial cell matrix under flow conditions is not dependent on platelet glycoprotein IV. Blood, 1994;83:3240 4.
  • 74
    Kehrel B, Kronenberg A, Rauterberg Jet al. Platelets deficient in glycoprotein IIIb aggregate normally to collagens type I and III but not to collagen type V. Blood, 1993;82:3364 70.
  • 75
    Ooshima A. Collagen B-chain: increased proportion in human atherosclerosis. Science, 1981;213:666 8.
  • 76
    Chiang TM & Kang AH. Isolation and purification of collagen α1 (I) receptor from human platelet membrane. J Biol Chem, 1982;257:7581 6.
  • 77
    Chiang TM, Kang AH, Dale JB, Beachy EH. Immunochemical studies of the purified human platelet receptor for the α1 (I) -chain of chick skin collagen. J Immunol, 1984;133:872 6.
  • 78
    Chiang TM, Jin A, Kang AH. Platelet–collagen interaction. Inhibition by a monoclonal antibody raised against collagen receptor. J Immunol, 1987;139:887 92.
  • 79
    Chiang TM, Rinaldy A, Kang AH. Cloning, characterization, and functional studies of a non-integrin platelet receptor for type I collagen. J Clin Invest, 1997;100:514 21.
  • 80
    Chiang TM & Kang AH. A synthetic peptide derived from the sequence of a type I collagen receptor inhibits type I collagen-mediated platelet aggregation. J Clin Invest, 1997;100:2079 84.
  • 81
    Deckmyn E, Von Houtte E, Vermylen J. Disturbed platelet aggregation to collagen associated with an antibody against an 85/90 kD platelet glycoprotein in a patient with prolonged bleeding time. Blood, 1992;79:1466 71.
  • 82
    Brass LF, Manning DR, Cichowski K, Abrams CS. Signaling through G proteins in platelets: to the integrins and beyond. Thromb Haemost 1997;78:581 9.
  • 83
    Rhee SG & Bae YS. Regulation of phosphoinositide-specific phospholipase C isoenzymes. J Biol Chem, 1997;272:15045 8.
  • 84
    Blake RA, Schieven GL, Watson SP. Collagen stimulates tyrosine phosphorylation of phospholipase C-gamma 2 but not phospholipase C-gamma 1 in human platelets. FEBS Lett, 1994;353:212 6.
  • 85
    Daniel JL, Dangelmaier C, Smith JB. Evidence for a role for tyrosine phosphorylation of phospholipase C gamma 2 in collagen-induced platelet cytosolic calcium mobilization. Biochem J, 1994;302:617 22.
  • 86
    Smith JB, Dangelmaier C, Daniel JL. Elevation of c-AMP in human platelets inhibits thrombin- but not collagen-induced tyrosine phosphorylation. Biochem Biophys Res Commun, 1993;191:695 700.
  • 87
    Shattil SJ, Ginsberg MH, Brugge JS. Adhesive signaling in platelets. Curr Opin Cell Biol, 1994;6:695 704.
  • 88
    Yanaga F, Poole A, Asselin Jet al. Syk interacts with tyrosine-phosphorylated proteins in human platelets activated by collagen and cross-linking of the Fc gamma-IIA receptor. Biochem J, 1995;311:471 8.
  • 89
    Fujii C, Yanagi S, Sada K, Nagai K, Taniguchi T, Yamamaura H. Involvement of protein-tyrosine kinase p72Syk in collagen-induced signal transduction in platelets. Eur J Biochem, 1994;226:243 8.
    Direct Link:
  • 90
    Gibbins JM, Briddon S, Shutes Aet al. The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor γ-chain and linker for activation of T cells (LAT) in platelets stimulated by collagen and convulxin. J Biol Chem, 1998;273:34437 43.
  • 91
    Zhang W, Sloan-Lancaster J, Kitchen J, Trible RP, Samelson LE. LAT: the ZAP-70 tyrosine kinase substrate that links T Cell receptor to cellular activation. Cell, 1998;92:83 92.
  • 92
    Reth M. Antigen receptor tail clue. Nature, 1989;338:383 4.
  • 93
    Gibbins JM, Asselin J, Farndale R, Barnes M, Law C-L, Watson SP. Tyrosine phophorylation of the Fc receptor γ-chain in collagen stimulated platelets. J Biol Chem, 1996;271:18095 9.
  • 94
    Morton HC, Van Den Herik-Oudijk IE, Vossebeld Pet al. Functional association between the human myeloid immunoglobulin A Fc receptor (CD89) and FcR γ-chain. J Biol Chem, 1995;270:29781 7.
  • 95
    Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell, 1994;76:519 29.
  • 96
    Shiue L, Zoller MJ, Brugge JS. Syk is activated by phosphotyrosine-containing peptides representing the tyrosine-based activation motifs of the high affinity receptor for IgE. J Biol Chem, 1995;270:10498 502.
  • 97
    Van Vugt MJ, Heijnen AF, Capel PJet al. FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. Blood, 1996;87:3593 9.
  • 98
    Poole A, Gibbins JM, Turner Met al. The Fc receptor γ-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO, 1997;16:2333 41.
  • 99
    Morton LF, Hargreaves PG, Farndale RW, Young RD, Barnes MJ. Integrin α2β1-independent activation of platelets by collagen: collagen tertiary (triple helical) and quaternary (polymeric) structures are sufficient alone for activity . Biochem J, 1995;306:337 44.
  • 100
    Asselin J, Gibbins JM, Achinson Met al. A collagen-like peptide stimulates tyrosine phosphorylation of syk and phospholipase Cγ2 in platelets independent of the integrin α2β1. Blood, 1997;89:1235 42.
  • 101
    Ichinohe T, Takayama H, Ezumi Y, Yanagi S, Yamamura H, Okuma M. Cyclic AMP-insensitive activation of c-Src and Syk protein-tyrosine kinases through platelet membrane glycoprotein VI. J Biol Chem, 1995;270:28029 36.
  • 102
    Liebenhoff U, Brockmeier D, Presek P. Substrate affinity of the protein tyrosine kinase pp. 60c-src is increased on thrombin stimulation of human platelets. Biochem J, 1993;295:41 8.
  • 103
    Clark EA, Shattil SJ, Ginsberg MH, Bolen J, Brugge JS. Regulation of the protein tyrosine kinase pp. 72syk by platelet agonists and the integrin alpha IIb beta 3. J Biol Chem, 1994;269:28859 64.
  • 104
    Ichinohe T, Takayama H, Ezumi Yet al. Collagen-stimulated activation of Syk but not c-Src is severly compromised in human platelets lacking membrane glycoprotein VI. J Biol Chem, 1997;272:63 8.
  • 105
    Gibbins JM, Okuma M, Farndale R, Barnes M, Watson SP. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor γ-chain. FEBS Lett, 1997;413:255 9.
  • 106
    Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor γ-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem, 1997;272:23528 31.
  • 107
    Polgár J, Clemetson JM, Kehrel BEet al. Platelet activation and signal transduction by convulxin, a C-type lectin from crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. J Biol Chem, 1997;272:13576 83.
  • 108
    Ezumi Y, Shindoh K, Tsuji M, Takayama H. Physical and functional association of the Src famiy kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor γ chain complex on human platelets. J Exp Med, 1998;188:267 76.
  • 109
    Hanke JH, Gardner JP, Dow RLet al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and Fyn-dependent T cell activation. J Biol Chem, 1996;271:695 701.
  • 110
    Briddon SJ & Watson SP. Evidence for the involvement of p59fyn and p53/56lyn in collagen receptor signalling in human platelets. Biochem J, 1999;338:203 9.
  • 111
    Clements JL, Lee JR, Gross Bet al. Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice. J Clin Invest, 1999;103:19 25.
  • 112
    Jackman JK, Motto DG, Sun Qet al. Molecular cloning of SLP-76, a 76-kDa tyrosine phosphoprotein associated with Grb2 in T cells. J Biol Chem 1995;270:7029 32.
  • 113
    Yablonski D, Kuhne MR, Kadlecek T, Weiss A. Uncoupling of nonreceptor tyrosine kinases from PLC-gamma1 in an SLP-76- deficient T cell. Science, 1998;281:413 6.
  • 114
    Clements JL, Yang B, Ross-Barta SEet al. Requirement for the leukocyte-specific adapter protein SLP-76 for normal T cell development. Science, 1998;281:416 9.
  • 115
    Pivniouk V, Tsitsikov E, Swinton P, Rathbun G, Alt FW, Geha RS. Impaired viability and profound block in thymocyte development in mice lacking the adaptor protein SLP-76. Cell, 1998;94:229 38.
  • 116
    Gross BS, Lee JR, Clements JLet al. Tyrosine phosphorylation of SLP-76 is downstream of Syk following stimulation of the collagen receptor in platelets. J Biol Chem, 1999;274:5963 71.
  • 117
    Rittenhouse SE. Phosphoinositide 3-kinase activation and platelet function. Blood, 1996;88:4401 14 [erratum: Blood, 1997;89:3075].
  • 118
    Keely PJ & Parise LV. The α2β1 integrin is a necessary co-receptor for collagen-induced aktivation of syk and the subsequent phosphorylation of phospholipase Cγ2 in platelets . J Biol Chem, 1996;271:26668 76.
  • 119
    Kamiguti AS, Markland FS, Zhou Q, Laing GD, Theakston RDG, Zuzel M. Proteolytic cleavage of the β1 subunit of platelet α2β1 integrin by the metalloproteinase jararhagin compromises collagen-stimulated phosphorylation of pp. 72syk. J Biol Chem, 1997;272:32599 605.
  • 120
    Kelton JG, Sheridan D, Santos Aet al. Heparin-induced thrombocytopenia: laboratory studies. Blood, 1988;72:925 30.
  • 121
    Sullam PM, Hyun WC, Szollosi J, Dong J, Foss WM, Lopez JA. Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor FcgammaRIIA on the platelet plasma membrane. J Biol Chem, 1998;273:5331 6.
  • 122
    Huang MM, Bolen JB, Barnwell JW, Shattil SJ, Brugge JS. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc Natl Acad Sci USA, 1991;88:7844 8.
  • 123
    Aiken ML, Ginsberg MH, Byers-Ward V, Plow EF. Effects of OKM5, a monoclonal antibody to glycoprotein IV, on platelet aggregation and thrombospondin surface expression. Blood, 1990;76:2501 9.
  • 124
    Trelstad R & Carvalho A. Type IV and type ‘A-B’ collagens do not elicit platelet aggregation or the serotonin release reaction. J Lab Clin Med, 1979;93:499 504.
  • 125
    Chiang TM, Seyer JM, Kang AH. Collagen–platelet interaction: separate receptors sites for types I and III collagen. Thromb Res, 1993;71:443 56.
  • 126
    Huang TF, Liu CZ, Yang SH. Aggretin, a novel platelet-aggregation inducer from snake (Calloselasma rhodostoma) venom, activates phospholipase C by acting as a glycoprotein Ia/IIa agonist. Biochem J, 1995;309:1021 7.
  • 127
    Asselin J, Knight CG, Farndale RW, Barnes MJ, Watson SP. Monomeric (glycine-proline-hydroxyproline) 10 repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein VI. Biochem J, 1999;339:413 8.
  • 128
    Knight CG, Morton LF, Onley DJet al. Collagen–platelet interaction: Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen. Cardiovasc Res, 1999;41:450 7.
  • 129
    Clemetson JM, Polgar J, Magnenat E, Wells TNC, Clemetson KJ. The platelet collagen receptor glycoprotein VI is a member fo the immunoglobulin superfamily closely related to Fc alpha R and the natural killer receptors. J Biol Chem, 1999;274:29019 24.